RESULTS OF INTRAVITREAL RANIBIZUMAB WITH A PRN REGIMEN IN THE TREATMENT OF EXTRAFOVEAL AND JUXTAFOVEAL NEOVASCULAR MEMBRANES IN AGE-RELATED MACULAR DEGENERATIONGiacomelli, Giovanni MD; Giansanti, Fabrizio MD; Finocchio, Lucia MD; Biagini, Ilaria CO; Bacherini, Daniela MD; Virgili, Gianni MD; Menchini, Ugo MDRetina: May 2014 - Volume 34 - Issue 5 - p 860–867 doi: 10.1097/IAE.0000000000000007 Original Study Abstract In Brief Author Information Abstract Purpose: To evaluate the efficacy of intravitreal ranibizumab with a “pro re nata” regimen in the treatment of nonsubfoveal neovascular membranes secondary to age-related macular degeneration. Methods: Retrospective noncomparative case series. Thirty-one eyes with naive nonsubfoveal neovascularization secondary to age-related macular degeneration were consecutively enrolled and treated with ranibizumab intravitreal injections according to a pro re nata regimen. The follow-up was performed monthly up to 6 months and quarterly up to 2 years (25 patients). Early treatment diabetic retinopathy study best-corrected visual acuity and lesion size analysis with fluorescein angiography were recorded. Results: The mean baseline early treatment diabetic retinopathy study best-corrected visual acuity worsened from 20/40 (0.28 logMAR) at baseline to 20/50 (0.42 logMAR) at 1-year follow-up and 20/60 (0.53 logMAR) at 2-year follow-up. The mean lesions size nearly doubled from baseline at the 2-year follow up (1.19–2.47 mm2). Twenty-two patients had one or more recurrences at 1-year follow-up. All 25 patients developed a recurrence at 2 years with 7 cases developing a recurrence by 12 months. Twelve cases progressed to subfoveal lesions by the 24-month visit. Conclusion: Other regimens described in the literature might result in a more the satisfactory outcome using more frequent follow-up and more frequent intravitreal injections. In Brief Intravitreal ranibizumab with a &#x201C;pro re nata&#x201D; regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration needs a monthly follow-up over at least 2 years. Author Information Department of Specialistic Surgical Sciences, Eye Clinic, University of Florence, Florence, Italy. Reprint requests: Giovanni Giacomelli, MD, Department of Specialistic Surgical Sciences, Eye Clinic, University of Florence, Viale Morgagni 85, Florence 50134, Italy; e-mail: email@example.com None of the authors have any financial/conflicting interests to disclose. © 2014 by Ophthalmic Communications Society, Inc.